Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 1, 2022

Mesh Bio, MultiOmic partner to develop chronic metabolic disease medicines

Digital health start-up Mesh Bio has collaborated with drug discovery company MultiOmic Health to use artificial intelligence (AI) for developing precision medicines and diagnostics for chronic metabolic disease.

Mesh Bio and MultiOmic Health will use artificial intelligence to develop precision medicines and diagnostics for chronic metabolic disease. Credit: Mesh Bio Pte. Ltd.